Expert Interview
Discussing AATD and COPD, focusing on Inhibrx's INBRX-101 and Verona's ensifentrine
Ticker(s): INBX, VRNAInstitution: UCLA
- Assistant Professor & Medical Director, Liver Transplant Intensive Care Unit ,Medical Director, COPD Program UCLA Division of Pulmonary and Critical Care Medicine.
- Treats over 100 Alpha-1 patients and runs alpha-1 CRC clinic.
- Has been a PI on multiple AATD trials; as a Medical Director of COPD Program at the David Geffen School of Medicine at UCLA, focuses and leads clinical and research projects in COPD, alpha-1 antitrypsin deficiency syndrome and lung nodule/lung cancer.
Roughly how many patients with AATD do you manage? With COPD?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for INBRX-101? For ensifentrine?
Added By: c_admin As far as the primary endpoint and this 32-week period, how likely do you think it is that they will exceed the plasma-derived concentration of AAT?
Plasma-derived, that's going to drop off as far as number of days at steady-state. Do you think that's equally as likely that they can show superiority there?
Added By: catalin_adminIf this did get approved, would you use it instead of plasma in most all your patients, or how do you think you'd use it?
Added By: catalin_adminHow many chronic patients do you currently manage or is managed also at UCLA?
f they hit these endpoints, does this give them accelerated approval at the FDA, full approval? What other endpoints might the FDA want to see? What's your opinion on the regulatory path?
Added By: catalin_adminWhat do you think about the EMA requiring a lung CT densitometry?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
